Mercer Global Advisors’s MoonLake Immunotherapeutics MLTX Stock Holding History

Mercer Global Advisors’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$257K	Buy	+13,202	New	+$239K	﹤0.01%	2981

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Mercer Global Advisors's MLTX Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in MoonLake Immunotherapeutics (MLTX) in Q2 2026: 13,202 shares worth $257K. The stake represents ﹤0.01% of the portfolio and ranks #2981 among its holdings.

173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

Mercer Global Advisors held 13,202 shares of MoonLake Immunotherapeutics worth $257K as of Q2 2026.
MoonLake Immunotherapeutics was a new Mercer Global Advisors position in Q2 2026.
MoonLake Immunotherapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #2981 holding.
173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.